PROCTER & GAMBLE HEALTH | GLENMARK LIFE SCIENCES | PROCTER & GAMBLE HEALTH/ GLENMARK LIFE SCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 21.2 | 163.4% | View Chart |
P/BV | x | 10.6 | 4.7 | 225.6% | View Chart |
Dividend Yield | % | 2.0 | 2.6 | 77.9% |
PROCTER & GAMBLE HEALTH GLENMARK LIFE SCIENCES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
GLENMARK LIFE SCIENCES Mar-23 |
PROCTER & GAMBLE HEALTH/ GLENMARK LIFE SCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 534 | 1,004.8% | |
Low | Rs | 3,883 | 369 | 1,052.3% | |
Sales per share (Unadj.) | Rs | 740.7 | 176.4 | 420.0% | |
Earnings per share (Unadj.) | Rs | 138.2 | 38.1 | 362.7% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 41.5 | 373.5% | |
Dividends per share (Unadj.) | Rs | 95.00 | 21.00 | 452.4% | |
Avg Dividend yield | % | 2.1 | 4.7 | 44.2% | |
Book value per share (Unadj.) | Rs | 447.6 | 174.0 | 257.3% | |
Shares outstanding (eoy) | m | 16.60 | 122.53 | 13.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 2.6 | 243.9% | |
Avg P/E ratio | x | 33.5 | 11.8 | 282.4% | |
P/CF ratio (eoy) | x | 29.8 | 10.9 | 274.2% | |
Price / Book Value ratio | x | 10.3 | 2.6 | 398.0% | |
Dividend payout | % | 68.7 | 55.1 | 124.7% | |
Avg Mkt Cap | Rs m | 76,761 | 55,321 | 138.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 1,802 | 114.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 21,612 | 56.9% | |
Other income | Rs m | 184 | 290 | 63.5% | |
Total revenues | Rs m | 12,480 | 21,902 | 57.0% | |
Gross profit | Rs m | 3,247 | 6,423 | 50.6% | |
Depreciation | Rs m | 281 | 421 | 66.8% | |
Interest | Rs m | 8 | 5 | 140.8% | |
Profit before tax | Rs m | 3,142 | 6,286 | 50.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 1,616 | 52.4% | |
Profit after tax | Rs m | 2,295 | 4,670 | 49.1% | |
Gross profit margin | % | 26.4 | 29.7 | 88.8% | |
Effective tax rate | % | 27.0 | 25.7 | 104.9% | |
Net profit margin | % | 18.7 | 21.6 | 86.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 23,687 | 49.4% | |
Current liabilities | Rs m | 6,791 | 10,228 | 66.4% | |
Net working cap to sales | % | 40.0 | 62.3 | 64.3% | |
Current ratio | x | 1.7 | 2.3 | 74.5% | |
Inventory Days | Days | 263 | 2 | 16,270.1% | |
Debtors Days | Days | 343 | 136 | 252.1% | |
Net fixed assets | Rs m | 10,617 | 8,518 | 124.6% | |
Share capital | Rs m | 166 | 245 | 67.7% | |
"Free" reserves | Rs m | 7,265 | 21,070 | 34.5% | |
Net worth | Rs m | 7,431 | 21,315 | 34.9% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 32,205 | 69.3% | |
Interest coverage | x | 409.1 | 1,150.2 | 35.6% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.7 | 82.1% | |
Return on assets | % | 10.3 | 14.5 | 71.0% | |
Return on equity | % | 30.9 | 21.9 | 141.0% | |
Return on capital | % | 42.4 | 29.5 | 143.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 9,691 | 15.1% | |
Fx outflow | Rs m | 1,605 | 5,001 | 32.1% | |
Net fx | Rs m | -140 | 4,689 | -3.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 3,134 | 75.3% | |
From Investments | Rs m | -215 | -1,541 | 13.9% | |
From Financial Activity | Rs m | -985 | -3,876 | 25.4% | |
Net Cashflow | Rs m | 1,160 | -2,283 | -50.8% |
Indian Promoters | % | 0.0 | 82.9 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 6.4 | 311.5% | |
FIIs | % | 6.2 | 5.0 | 124.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 17.2 | 280.9% | |
Shareholders | 56,778 | 156,183 | 36.4% | ||
Pledged promoter(s) holding | % | 0.0 | 9.5 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | GLENMARK LIFE SCIENCES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 8.21% | 0.45% |
1-Month | -1.15% | 7.37% | 2.55% |
1-Year | 0.73% | 75.47% | 56.14% |
3-Year CAGR | -8.76% | 2.85% | 15.22% |
5-Year CAGR | 4.97% | 1.70% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the GLENMARK LIFE SCIENCES share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of GLENMARK LIFE SCIENCES the stake stands at 82.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of GLENMARK LIFE SCIENCES.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
GLENMARK LIFE SCIENCES paid Rs 21.0, and its dividend payout ratio stood at 55.1%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of GLENMARK LIFE SCIENCES.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.